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Abstract 
Background: Once considered an affliction of people in high-income countries, diabetes mellitus is increasingly 
seen as a global epidemic. However, for many countries very little is known about the prevalence of diabetes and 
its complications. This study aims to estimate the prevalence of diabetes, and diabetic retinopathy, in adults in 
Timor-Leste.
Methods: From March 2013 to May 2014, adult patients being assessed for cataract surgery at the Sentru Matan 
Nasional (National Eye Centre) in Dili, Timor-Leste had a point-of-care HbA1c measurement performed on the DCA 
Vantage device (Siemens Ltd) under a quality framework. A diagnostic cut-off of 6.5% (48 mmol/mol) HbA1c was 
used for diagnosis of diabetes. Ocular examination, blood pressure, demographic and general health data were also 
collected. Diabetic retinopathy assessment was carried out by ophthalmologists.
Results: A total of 283 people [mean age 63.6 years (range 20–90 years)] were tested and examined during the study 
period. Forty-three people (15.2%) were found to have diabetes, with a mean HbA1c of 9.5% (77 mmol/mol). Of these, 
27 (62.9%) were newly diagnosed, with a mean HbA1c of 9.7% (83 mmol/mol) and a range of 6.6–14% (49–130 mmol/
mol). Nearly half (48.1%) of people newly diagnosed with diabetes had an HbA1c over 10.0% (86 mmol/mol). Of those 
with known diabetes, only 68.8% were receiving any treatment. Mean HbA1c for treated patients was 9.9% (85 mmol/
mol). Diabetic retinopathy was identified in 18.6% of people with diabetes, of whom half had no previous diagnosis of 
diabetes.
Conclusions: This study estimates the prevalence of diabetes at 15% in adults in Timor-Leste, a substantial propor-
tion of whom have evidence of diabetic retinopathy. This is consistent with regional estimates. With the majority of 
patients undiagnosed, and management of people known to have diabetes largely inadequate, point-of-care testing 
is a valuable tool to assist with diabetes case detection and management. Whilst only a preliminary estimate, our 
data provides important impetus for further investigation of the prevalence and impact of diabetes in Timor-Leste. It 
provides guidance that further investment is required in expanding testing, as well as in prevention and treatment.
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Background
Diabetes is becoming one of the leading causes of mor-
bidity and mortality worldwide. Once considered a dis-
ease of affluent countries, rates of diabetes are now 
increasing in low- and middle-income countries. It is 
estimated that worldwide around 346 million people suf-
fer from diabetes, with 80% of these in low- and middle-
income countries [1].
Interestingly, the pattern of development of diabetes in 
Asian countries is also more severe, with the disease typi-
cally appearing at a younger age, and generally with more 
devastating consequences [2]. Apart from the human 
toll, it is possible that hard-won economic gains could be 
undermined by morbidity in the working age population.
Timor-Leste is one of the world’s newest countries, 
having regained its independence in 1999 following a 
referendum. It was recognized by the United Nations 
in 2002. During the 24-year period of Indonesian rule 
there were between 102,800 and 183,000 excess civil-
ian deaths [3]. After the vote for independence almost 
the entire health workforce left, and around 70% of all 
buildings were destroyed [4]. The country faces many 
challenges with 37.4% living below the international 
poverty line of US$1.25/day, and 50% literacy [5]. Hun-
ger, malnutrition and child stunting are rife [6]. How-
ever, at the same time urbanization and dietary habits 
are changing rapidly. Although Timor-Leste remains a 
predominantly rural nation (70.4%), its rate of urbani-
zation (4.18% per year) exceeds its growth rate (2.40% 
per year), largely driven by migration to Dili in search of 
cash employment [7].
Timor-Leste is currently in the process of building 
an entire health system from the ground up. At present 
health monitoring is weak, and resources for health are 
poor. Challenges continue in the prevention and treat-
ment of communicable diseases, and non-communicable 
diseases such as diabetes.
Very little research has been undertaken to investigate 
the prevalence of diabetes and the impact of its sequelae 
in Timor-Leste. One pilot study in 2010 estimated preva-
lence to be approximately 5% in adults aged 40 years or 
over, with 74% of patients identified previously undiag-
nosed [8]. Anecdotally, doctors working in Timor-Leste, 
particularly in Dili, believe that the prevalence of dia-
betes is higher than previously reported. Furthermore, 
this seems low compared to Timor-Leste’s neighbouring 
countries. The International Diabetes Federation esti-
mates prevalence in the Western Pacific region amongst 
adults aged 20–79 years as 8.6% [9]. Data from Indonesia 
is inconsistent but one study conducted in a population 
aged over 20 years in Ternate City, North Moluccas Prov-
ince, Indonesia estimated prevalence at 19.6%, based on 
fasting glucose [10].
If left undiagnosed and untreated, diabetes can be a 
devastating disease. Microvascular end organ damage 
is the final common pathway, resulting in infections and 
amputations via neuropathy, renal failure via nephropa-
thy, and blindness via retinopathy. This occurs via a num-
ber of pathways including activation of protein kinase 
C (PKC), increased expression of vascular endothe-
lial growth factor (VEGF) [11] and advanced glycation 
end products (AGE) [12]. Glycation of proteins, lipids, 
nucleic acids and other molecules interfere with normal 
functioning. The retina lends itself particularly well to the 
monitoring of microvascular disease, as the vessels can 
be monitored by clinicians.
A temporal pattern of the emergence of diabetes melli-
tus and the development of diabetic retinopathy has been 
shown. Therefore, examination of patients for diabetic 
retinopathy gives some estimate of the length of time that 
they have had diabetes mellitus, and the severity of their 
disease. Although estimates vary widely, it is thought that 
almost all patients with Type I diabetes and more than 
60% of patients with Type II diabetes will have retinopa-
thy after a decade of disease [13]. Across published stud-
ies prevalence of retinopathy in known diabetes is 27.9%, 
and 10.5% in newly diagnosed diabetes [14].
An important step forward in the monitoring of dia-
betes was the global standardization of HbA1c test-
ing methods, resulting in a strong push by international 
expert groups and professional organisations to use the 
HbA1c tests for the diagnosis of diabetes [15, 16]. In 
2010 the American Diabetes Association released new 
guidelines stating that diabetes need not be diagnosed by 
the gold standard oral glucose tolerance test, but could 
instead be diagnosed using glycated haemoglobin, with 
an HbA1C of ≥6.5% (48 mmol/mol) as the cut off point 
for the diagnosis of diabetes [17].
Considerable work has been conducted across many 
parts of the world, primarily using receiver-operator-
curves to compare the oral glucose tolerance test with 
HbA1c, to create local diagnostic cut-off points for 
the diagnosis of diabetes. All of these revised estimates 
have been around or lower than 6.5% (48  mmol/mol). 
This indicates that using a diagnostic cut off of 6.5% 
(48  mmol/mol) should provide a good, if conservative, 
estimate of the proportion of patients with diabetes [18].
Furthermore, the development of rapid point-of-care 
HbA1c tests has made opportunistic testing for diabetes 
mellitus much easier. This is of considerable importance 
in a country such as Timor-Leste where the health sys-
tem is weak, laboratory access is limited, and patients 
may have very few interactions with the health system. 
Indeed, there is no HbA1c test available at the Hospital 
Nacional Guido Valadares, other than at the eye clinic. 
Through a partnership with the Flinders University 
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International Centre for Point-of-Care Testing (iPOCT), 
the National Eye Centre in Dili was able to conduct point-
of-care testing for HbA1c using the DCA Vantage (Sie-
mens Ltd) as part of an international model developed 
by iPOCT called the ACE (Analytical and Clinical Excel-
lence) Program. This device has been shown to produce 
point-of-care test results that are analytically equivalent 
to laboratory measurements of HbA1c [19–21].
In addition to diabetes, another globally important 
non-communicable disease is arterial hypertension. The 
American Heart Association defines hypertension as a 
blood pressure of greater than 140/90 [22]. Hypertension 
is associated with an increased risk of heart disease and 
stroke. Furthermore, hypertension is a potent synergistic 
factor in the worsening of diabetic retinopathy [23].
Cataract is an important cause of preventable blindness 
across the world, especially in low-income countries [24]. 
Formation of cataract is multi-factorial, with the most 
important risk factor by far being advancing age, though 
also including diabetes and smoking [25]. In Timor-Leste 
cataract is the leading cause of blindness [26]. Further-
more, the eye care system is one of the most well devel-
oped parts of the health care system in Timor-Leste with 
a permanent National Eye Centre in Dili and outreach to 
all of the districts. Therefore, the population of patients 
presenting to the National Eye Centre for workup for cat-
aract presents a very useful opportunistic population in 
which to study the prevalence of diabetes.
Methods
In this study health professional staff from the National 
Eye Centre performed point-of-care HbA1c testing on all 
patients being assessed for cataract surgery at the Cen-
tre in Dili, Timor-Leste. Staff undertook a training and 
competency assessment program and performed regu-
lar quality control testing (as part of their participation 
in the Analytical and Clinical Excellence [ACE] Program) 
to monitor analytical performance of the DCA Vantage 
device. We used a level of ≥6.5% (48 mmol/mol) as diag-
nostic of diabetes. Additionally, we included patients 
diagnosed and treated for diabetes mellitus, but who now 
had an HbA1c of <6.5% (48 mmol/mol). Patients over the 
age of 18 were eligible for inclusion in this study.
Demographic data including age and sex were col-
lected. Data regarding reported family history and medi-
cation history was also collected from patients identified 
with diabetes.
Clinical examination was performed including visual 
acuity, intraocular pressure, anterior and posterior seg-
ment examination, and sphygmomanometry. When 
the retina could not be examined, patients were asked 
to present again for examination after cataract surgery. 
When diabetic retinopathy was found it was graded by an 
ophthalmologist according to the International Clinical 
Disease Severity Scale for Diabetic Retinopathy [27].
Patients who required examination further to stand-
ard care for cataract surgery provided written informed 
consent. Consent forms were approved in the human 
research ethics approval process, and were available in 
Tetun and English. Data was de-identified and securely 
stored.
Patients identified with diabetes, hypertension, or the 
end organ consequences of these diseases were referred 
to the internal medicine clinic at Guido Valadares 
National Hospital, or to a local doctor.
Ethics approval for this study was received from the 
Timor-Leste Ministry of Health, and the tenets of the 
Declaration of Helsinki were abided by at all times.
Results
283 patients were included in the study over a 14-month 
period between March 2013 and May 2014. This repre-
sents a consecutive series of adult cataract patients, with 
exceptions for periods of time when the HbA1c device 
was unavailable for testing (due mainly to delays in deliv-
ering testing reagents).
Slightly more than half (58.7%) of patients were 
male. The age range was 20–90 years, with a median of 
66  years, and a mean of 63.6  years. Male patients had 
a slightly greater age range (20–90  years) than female 
patients (31–86 years) (Table 1).
Reported HbA1c results ranged from 4.2 to 14% (22–
130  mmol/mol) (with 14% being the upper limit of the 
device’s measurement range) (Table 2). For the recruited 
population, the mean HbA1c was 6.1% (43  mmol/mol). 
For patients without diabetes the mean HbA1c was 5.5% 
(37 mmol/mol).
Forty-three patients (15.2%) were found to have diabe-
tes, with a mean HbA1c of 9.5% (80 mmol/mol). Of these, 
27 (62.9%) were newly diagnosed, with a mean HbA1c 
of 9.7% (83  mmol/mol) and a range of values from 6.6 
to 14% (49–130 mmol/mol). Thirteen of the newly diag-
nosed patients with diabetes (48.1%) had an HbA1c over 
10.0% (86 mmol/mol).
Amongst the 16 patients with known diabetes, the 
duration of diagnosis ranged from 2 months to 13 years, 
with a mean duration of 4.9  years. Eleven patients 
Table 1 Demographic Data
Female Male
Proportion of total 283 subjects (%) 41.3 58.7
Mean age (years) 63.6
Median age (years) 66
Age range (years) 20–90
Page 4 of 6Dawkins et al. BMC Res Notes  (2015) 8:249 
(68.8%) were on treatment, either medical or lifestyle. 
Mean HbA1c for treated patients was 9.9% (85  mmol/
mol). Three treated patients had achieved HbA1c <7.0% 
(53 mmol/mol).
The point-of-care device’s performance was analyti-
cally sound, with 100% of quality control test results for 
HbA1c being within the goal for allowable limits for 
acceptable analytical performance recommended for lab-
oratories by the Royal College of Pathologists of Austral-
asia’s Quality Assurance Program for Glycohaemoglobin.
Diabetic retinopathy was identified in eight of the 43 
patients with diabetes (18.6%), including four with previ-
ously undiagnosed diabetes. No proliferative retinopathy 
was found, though severe non-proliferative retinopathy 
was found in one patient who was previously undiagnosed.
Blood pressure was measured and recorded for 245 
patients (86.6%). The range of systolic blood pressure 
(SBP) was 74–220  mmHg, with a mean of 136  mmHg. 
114 patients (46.5%) had SBP  ≥140  mmHg, systolic 
hypertension. Amongst those patients with diabe-
tes, the SBP range was 90–195  mmHg, with a mean of 
143  mmHg (values were available for 83.3% of diabetic 
patients).
Discussion
This study shows the great potential burden of diabe-
tes amongst adults in Timor-Leste. The prevalence in 
our population of unselected adult cataract patients was 
15.2%, much higher than a previous estimate, but similar 
to regional estimates.
Furthermore, we show that the vast bulk of people with 
diabetes are undiagnosed (62.8%), and those that are diag-
nosed are inadequately managed—either untreated or 
inadequately treated. This is likely due to poor access to 
diagnostic testing and monitoring, and unreliable medi-
cation supply. The issues around management of diabe-
tes are clearly highlighted by the finding that the group of 
treated patients had higher mean HbA1c than those that 
were newly diagnosed at the National Eye Centre.
Point-of-care testing has provided a clinically useful 
and analytically sound tool to assist the diagnosis of dia-
betes in a country where HbA1c is not available through 
any hospital laboratory services in Timor-Leste. Ongo-
ing access should mean that physicians can better assist 
patients to manage levels of glycaemia, provided access 
to medication also improves.
In this study the rates of diabetic retinopathy in known 
(25.0%) and previously undiagnosed (14.8%) patients 
with diabetes are comparable to reported values for these 
groups in the literature [14]. We therefore conclude that 
other microvascular complications of diabetes such as neu-
ropathy, nephropathy, cardiac and central nervous system 
complications are likely to be at similar to literature rates. 
Whilst this requires significant further study, it is of signifi-
cant consequence to the health care system in Timor-Leste.
Although the study was not designed to report on 
systemic hypertension, the proportion of patients 
with hypertension in this population (46.5% with 
SBP ≥140 mmHg) is cause for concern in terms of likely 
consequences for morbidity and mortality.
An important limitation of this study is that it was 
undertaken in a specific population, a population of cat-
aract surgery patients. However, given that cataract is a 
relatively ubiquitous disease in older age, and because 
diabetes is a disease of significant importance, we believe 
that our study population is a reasonable population in 
which to make an initial estimate of the prevalence of 
diabetes in adults in Timor-Leste. It is important to bear 
in mind the relationship between cataract and diabetes, 
and the increasing prevalence of diabetes with advancing 
age. Therefore, the prevalence of diabetes may be higher 
in our study population than the general population, 
and  additional  work should be undertaken in a broader 
population-based setting.
Another limitation of this study is that it was conducted 
in Dili, the capital city of Timor-Leste which is relatively 
more urbanised and less poor than rural districts. This 
makes it likely that rates of diabetes may be higher than 
Table 2 Diabetes and diabetic retinopathy in the adult cataract surgery population in Dili, Timor-Leste
Units All patients Patients without 
diabetes
Patients with diabetes HbA1c ≥6.5% (48 mmol/mol)




Number of subjects 283 240 43 27 16
Mean HbA1c (95% CI) % 6.1 (5.9–6.3) 5.5 (5.45–5.55) 9.5 (8.8–10.2) 9.7 (8.9–10.6) 9.2 (8.2–10.2)
mmol/mol 43 (41–45) 37 (36–37) 80 (73–88) 83 (74–92) 77 (66–88)
HbA1c range % 4.2–14 4.2–6.4 6.5–14 6.6–14 6.2–12.9
mmol/mol 22–130 22–46 48–130 49–130 44–117
Percentage of subjects with 
diabetic retinopathy
– – 18.6% (n = 8) 14.8% (n = 4) 25.0% (n = 4)
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in other parts of the country. However, internal migra-
tion to Dili, and other regional centres is proceeding at 
a rapid rate, as is economic development in Timor-Leste.
Conclusions
This study shows that, despite its status as a new and rela-
tively economically undeveloped country, the prevalence 
of diabetes in Timor-Leste is very likely at least similar 
to countries in the region. This is important because the 
prevalence has previously been unknown but thought to 
be low, and it has not been a focus for the health system.
Our data shows that diabetes, and likely other non-
communicable diseases such as systemic hypertension, 
are becoming an important source of morbidity and 
likely mortality in Timor-Leste as in other developing 
countries. Further epidemiological research is required 
to more accurately estimate the prevalence and burden of 
diabetes in Timor-Leste, but from our data it seems that 
left unchecked the humanitarian and economic burden 
will be very large in a fragile health system and economy.
This study shows that it is urgent that significant 
investment is made by the Government of Timor-Leste, 
as well as external donors, in health system strengthen-
ing to meet these emerging complex needs. Building 
greater on-ground capacity to undertake quality-assured 
point-of-care testing is one step to assist this investment. 
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